HR Execs on the Move

ArQule, Inc.

www.arqule.com

 
ArQule, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.arqule.com
  • 19 Presidential Way
    Woburn, MA USA '01801
  • Phone: 781.994.0300

Executives

Name Title Contact Details

Similar Companies

Mission Bio

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics.

Concert Medical

Concert Medical is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medivant Healthcare

Uniquely poised as a world class FDA registered outsourcing pharmaceutical manufacturer, Medivant offers the best in the industry when it comes to reliability and management, supply chain transparency, and lower total net cost. *dba Tailstorm Health, Inc. Our vials are made to the exact dosage specification allowing you to achieve a lower net cost of ordering, reducing total waste, and saving you money in the process. Our state of the art manufacturing facility has been completely designed from the ground up with the highest technology available, with full automation, and superior excellence, with highly trained staff experienced in top quality production.

Carolus Therapeutics

Carolus Therapeutics, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.